On CNBC’s “Halftime Report Final Trades,” Capital Wealth’s Kevin Simpson named The Coca-Cola Company (NYSE:KO) as his final trade.
Lending support to his choice, Barclays analyst Lauren Lieberman, on May 21, maintained Coca-Cola with an Overweight rating and raised the price target from $85 to $89.
In its first-quarter earnings report, Coca-Cola expanded its operating margins to 35%, up from 32.9% in the prior year. Furthermore, organic revenue climbed by 10%, highlighting the firm’s resilience and strong consumer focus despite broader macroeconomic uncertainty and persistent inflation.
Don’t forget to check out our premarket coverage here
Bill Baruch, founder and CIO of both Blue Line Capital, an investment advisor, and Blue Creek Capital Management, picked AbbVie Inc. (NYSE:ABBV).
As per the recent news, AbbVie, on May 29, announced European Commission authorization of expanded label for VENCLYXTO® (venetoclax) to include additional combinations in previously untreated chronic lymphocytic leukemia.
Jenny Van Leeuwen Harrington, chief executive officer of Gilman Hill Asset Management, LLC, recommended Sabra Health Care REIT, Inc. (NASDAQ:SBRA).
On the earnings front, Sabra Health Care, on April 29, posted better-than-expected results for the first quarter.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, named UnitedHealth Group Incorporated (NYSE:UNH) as his final trade.
Supporting his view, B of A Securities analyst Kevin Fischbeck, on June 4, upgraded UnitedHealth Group from Neutral to Buy and raised the price target from $420 to $450.
Price Action:
- Coca-Cola shares gained 3.5% to close at $79.48 on Friday.
- AbbVie shares rose 1% to settle at $227.23 during the session.
- Sabra Health Care shares gained 4.5% to close at $18.46 on Friday.
- UnitedHealth shares rose 0.8% to settle at $399.47 on Friday.
Photo via Shutterstock
Recent Comments